ClinicalTrials.gov

History of Changes for Study: NCT02854033
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol (ADNI3)
Latest version (submitted June 15, 2022) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 August 2, 2016 None (earliest Version on record)
2 September 7, 2016 Contacts/Locations, Study Status and References
3 October 31, 2016 Recruitment Status, Contacts/Locations, Study Status and Oversight
4 December 13, 2016 Contacts/Locations and Study Status
5 December 16, 2016 Contacts/Locations and Study Status
6 January 3, 2017 Contacts/Locations and Study Status
7 January 10, 2017 Contacts/Locations and Study Status
8 January 12, 2017 Contacts/Locations and Study Status
9 January 25, 2017 Contacts/Locations and Study Status
10 February 8, 2017 Study Status and Contacts/Locations
11 February 13, 2017 Contacts/Locations and Study Status
12 February 28, 2017 Contacts/Locations and Study Status
13 March 8, 2017 Contacts/Locations and Study Status
14 March 13, 2017 Contacts/Locations and Study Status
15 March 15, 2017 Contacts/Locations and Study Status
16 March 22, 2017 Contacts/Locations and Study Status
17 March 27, 2017 Contacts/Locations and Study Status
18 March 31, 2017 Contacts/Locations and Study Status
19 April 11, 2017 Contacts/Locations and Study Status
20 April 13, 2017 Contacts/Locations and Study Status
21 April 20, 2017 Contacts/Locations and Study Status
22 May 2, 2017 Contacts/Locations and Study Status
23 May 4, 2017 Contacts/Locations and Study Status
24 May 5, 2017 Contacts/Locations and Study Status
25 May 10, 2017 Contacts/Locations and Study Status
26 May 16, 2017 Contacts/Locations and Study Status
27 May 17, 2017 Contacts/Locations and Study Status
28 May 25, 2017 Contacts/Locations and Study Status
29 June 1, 2017 Study Status and Contacts/Locations
30 June 8, 2017 Contacts/Locations and Study Status
31 June 16, 2017 Contacts/Locations and Study Status
32 June 22, 2017 Contacts/Locations and Study Status
33 June 23, 2017 Contacts/Locations and Study Status
34 July 5, 2017 Contacts/Locations and Study Status
35 July 13, 2017 Contacts/Locations and Study Status
36 July 18, 2017 Contacts/Locations and Study Status
37 July 27, 2017 Contacts/Locations and Study Status
38 August 3, 2017 Contacts/Locations and Study Status
39 August 14, 2017 Contacts/Locations and Study Status
40 August 22, 2017 Contacts/Locations and Study Status
41 August 29, 2017 Contacts/Locations and Study Status
42 August 31, 2017 Contacts/Locations and Study Status
43 September 1, 2017 Contacts/Locations and Study Status
44 September 5, 2017 Contacts/Locations and Study Status
45 September 8, 2017 Contacts/Locations and Study Status
46 September 19, 2017 Contacts/Locations and Study Status
47 September 27, 2017 Contacts/Locations and Study Status
48 October 4, 2017 Study Status and Contacts/Locations
49 October 18, 2017 Contacts/Locations and Study Status
50 October 19, 2017 Contacts/Locations and Study Status
51 December 8, 2017 Contacts/Locations and Study Status
52 December 14, 2017 Contacts/Locations and Study Status
53 January 5, 2018 Contacts/Locations and Study Status
54 January 12, 2018 Contacts/Locations and Study Status
55 January 26, 2018 Contacts/Locations and Study Status
56 February 7, 2018 Contacts/Locations and Study Status
57 February 8, 2018 Contacts/Locations and Study Status
58 April 20, 2018 Contacts/Locations and Study Status
59 April 23, 2018 Contacts/Locations and Study Status
60 May 4, 2018 Contacts/Locations and Study Status
61 May 10, 2018 Contacts/Locations and Study Status
62 May 22, 2018 Contacts/Locations and Study Status
63 June 1, 2018 Study Status and Contacts/Locations
64 June 7, 2018 Contacts/Locations and Study Status
65 August 15, 2018 Contacts/Locations, Groups and Interventions, Study Status and Study Description
66 September 7, 2018 Contacts/Locations and Study Status
67 November 5, 2018 Study Status and Contacts/Locations
68 November 14, 2018 Contacts/Locations and Study Status
69 December 11, 2018 Contacts/Locations and Study Status
70 January 14, 2019 Contacts/Locations and Study Status
71 February 13, 2019 Contacts/Locations and Study Status
72 February 22, 2019 Contacts/Locations and Study Status
73 April 8, 2019 Contacts/Locations and Study Status
74 July 12, 2019 Contacts/Locations and Study Status
75 August 13, 2019 Study Status and Contacts/Locations
76 October 2, 2019 Contacts/Locations and Study Status
77 November 26, 2019 Contacts/Locations and Study Status
78 December 5, 2019 Contacts/Locations and Study Status
79 December 16, 2019 Contacts/Locations and Study Status
80 March 18, 2020 Contacts/Locations, Study Status, Eligibility and Groups and Interventions
81 September 14, 2020 Contacts/Locations and Study Status
82 November 5, 2020 Contacts/Locations and Study Status
83 April 26, 2021 Study Status, References, Contacts/Locations and Outcome Measures
84 October 27, 2021 Study Status and Contacts/Locations
85 November 15, 2021 Contacts/Locations and Study Status
86 February 24, 2022 Study Status and Contacts/Locations
87 May 4, 2022 Contacts/Locations and Study Status
88 June 15, 2022 Study Status and Contacts/Locations
Comparison Format:

Scroll up to access the controls

Study NCT02854033
Submitted Date:  August 2, 2016 (v1)

Open or close this module Study Identification
Unique Protocol ID: ATRI-001
Brief Title: Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol (ADNI3)
Official Title: Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol
Secondary IDs: U01AG024904 [U.S. NIH Grant/Contract]
Open or close this module Study Status
Record Verification: July 2016
Overall Status: Not yet recruiting
Study Start: August 2016
Primary Completion: August 2021 [Anticipated]
Study Completion: August 2021 [Anticipated]
First Submitted: July 27, 2016
First Submitted that
Met QC Criteria:
August 2, 2016
First Posted: August 3, 2016 [Estimate]
Last Update Submitted that
Met QC Criteria:
August 2, 2016
Last Update Posted: August 3, 2016 [Estimate]
Open or close this module Sponsor/Collaborators
Sponsor: University of Southern California
Responsible Party: Principal Investigator
Investigator: Paul Aisen
Official Title: Director, Alzheimer's Therapeutic Research Institute
Affiliation: University of Southern California
Collaborators: Northern California Institute of Research and Education
National Institute on Aging (NIA)
Alzheimer's Therapeutic Research Institute
Open or close this module Oversight
U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.
Detailed Description:

The overall goal of ADNI3 is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as the pathology evolves from normal aging through very mild symptoms, to mild cognitive impairment (MCI), to dementia. ADNI3 continues the previously funded AD Neuroimaging Initiative (ADNI1, ADNI-GO, and ADNI-2), and remains a public/private collaboration between academia and industry to study biomarkers of AD. ADNI will continue to inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios.

This is a non-randomized natural history non-treatment study. Participants will need to be 55 - 90 years, otherwise healthy with no neurologic disease such as Alzheimer's disease. Approximately 1070 - 2000 participants will be enrolled at approximately 59 sites in the United States and Canada. Approximately, 700 - 800 will be rollover participants from previous ADNI studies, and 370 - 1200 will be newly enrolled. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across the three cohorts.

Subjects will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (FDG, amyloid and tau) and MRI scans and cerebral spinal fluid (CSF) collection for up to 5 years.

Open or close this module Conditions
Conditions: Mild Cognitive Impairment (MCI)
Alzheimer's Disease (AD)
Keywords: amyloid
plaques
neuroimaging
biomarkers
cognition disorder
early detection
pre-dementia
dementia
Alzheimer's disease
tau
Open or close this module Study Design
Study Type: Observational
Observational Study Model: Cohort
Time Perspective: Prospective
Biospecimen Retention: Samples With DNA
Biospecimen Description: blood, urine, cerebrospinal fluid
Enrollment: 2000 [Anticipated]
Number of Groups/Cohorts 3
Open or close this module Groups and Interventions
Groups/Cohorts Interventions
Cognitively Normal (CN)
135-500 newly enrolled participants with no apparent memory problems, and 295-300 cognitively normal participants followed from the ADNI2 study
Mild Cognitive Impairment (MCI)
150 - 515 newly enrolled participants with mild cognitive impairment (MCI), and 275-320 MCI participants followed from the ADNI2 study
Mild Alzheimer's Disease dementia (AD)
85 - 85 newly enrolled participants with mild Alzheimer's disease (AD) dementia, and 130 - 150 mild AD participants followed from the ADNI2 study
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Rate of change in cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13)
[ Time Frame: 5 years ]

The ADAS-Cog is an in-person examiner-administered, structured scale that evaluates memory (word recall, word recognition), reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs).

Ratings of spoken language, language comprehension, word finding difficulty, and ability to remember test instructions are also obtained.

2. Rate of change in cognition as measured by the Logical Memory Test I and II
[ Time Frame: 5 years ]

3. Rate of change in cognition as measured by the Mini-Mental State Examinations (MMSE)
[ Time Frame: 5 years ]

The MMSE scale evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two overlapping pentagons.
Secondary Outcome Measures:
1. Rate of change in cognition as measured by the Cogstate Brief Battery (CBB)
[ Time Frame: 5 years ]

The Cogstate Brief battery (CBB) is a brief (10-15 minute) computerized cognitive battery developed by Cogstate (Cogstate Ltd. New Haven, CT, USA) that measures attention, speed of information processing, working memory and learning.
2. Rate of change in cognition as measured by the American National Adult Reading Test (ANART)
[ Time Frame: 5 years ]

The ANART estimates premorbid verbal intelligence (VIQ) in patients with dementia.
3. Rate of change in cognition as measured by the Montreal Cognitive Assessment (MoCA)
[ Time Frame: 5 years ]

The Montreal Cognitive Assessment test (MoCA) is a cognitive assessment designed to detect participants at the MCI stage of cognitive dysfunction.
4. Rate of change in cognition as measured by the Rey Auditory Verbal Learning Test
[ Time Frame: 5 years ]

The AVLT is a list-learning task, which assesses multiple cognitive parameters associated with learning and memory.
5. Rate of change in cognition as measured by the Trail Making Test: A and B
[ Time Frame: 5 years ]

6. Change in tau deposition as measured by 18F-AV-1451
[ Time Frame: 5 years ]

7. Change in amyloid deposition as measured by Florbetapir
[ Time Frame: 5 years ]

8. Change in amyloid deposition as measured by Florbetaben
[ Time Frame: 5 years ]

9. Rate of conversion to MCI or dementia due to AD
[ Time Frame: 5 years ]

10. Rates of change of glucose metabolism (FDG-PET)
[ Time Frame: 5 years ]

11. Change in Cerebral Spinal Fluid (CSF) Tau Biomarkers
[ Time Frame: 5 years ]

12. Change in brain structure using magnetic resonance imaging (MRI)
[ Time Frame: 5 years ]

Open or close this module Eligibility
Study Population: Cognitively normal (CN), mild cognitive impairment (MCI), and mild AD dementia participants.
Sampling Method: Probability Sample
Minimum Age: 55 Years
Maximum Age: 90 Years
Sex: All
Gender Based:
Accepts Healthy Volunteers: Yes
Criteria:

Inclusion Criteria (all CN participants):

  1. Participant with or without subjective memory complaints, verified by a study partner, beyond what one would expect for age
  2. Normal memory function documented by scoring above education adjusted cutoffs on the Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale -Revised (the maximum score is 25):
    1. 9 for 16 or more years of education
    2. 5 for 8-15 years of education
    3. 3 for 0-7 years of education
  3. Mini-Mental State Exam score between 24 and 30 inclusive (Exceptions may be made for participants with less than 8 years of education at the discretion of the Project Director)
  4. Clinical Dementia Rating = 0. Memory Box score must be 0
  5. Cognitively normal, based on an absence of significant impairment in cognitive functions or activities of daily living
  6. Stability of Permitted Medications for at least 4 weeks:
    1. Stable doses of antidepressants lacking significant anticholinergic side effects (if they are currently adequately treated for depressive symptoms and do not have a history of major depression within the past 1 years)
    2. Estrogen replacement therapy is permissible
    3. Gingko biloba is permissible, but discouraged
    4. Washout from psychoactive medication (e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening.

Inclusion Criteria (all MCI participants):

  1. Participant must express a subjective memory concern as reported by participant, or recalled by study partner or clinician.
  2. Abnormal memory function documented by scoring below education adjusted cutoffs on the Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale -Revised (the maximum score is 25):

    a. < 11 for 16 or more years of education b. ≤ 9 for 8-15 years of education c. ≤ 6 for 0-7 years of education

  3. Mini-Mental State Exam score between 24 and 30 inclusive (Exceptions may be made for participants with less than 8 years of education at the discretion of the Project Director)
  4. Clinical Dementia Rating = 0.5. Memory Box score must be at least 0.5
  5. General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's disease cannot be made by the site physician at the time of the Screening Visit
  6. Stability of Permitted Medications for at least 4 weeks:
    1. Stable doses of antidepressants lacking significant anticholinergic side effects (if they are currently adequately treated for depressive symptoms and do not have a history of major depression within the past 1 years)
    2. Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks prior to Screening Visit
    3. Estrogen replacement therapy is permissible
    4. Gingko biloba is permissible, but discouraged
    5. Washout from psychoactive medication (e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening.

Inclusion Criteria (all AD participants):

  1. Participant must express a subjective memory concern as reported by participant, or recalled by study partner or clinician.n.
  2. Abnormal memory function documented by scoring below education adjusted cutoffs on the Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale -Revised (the maximum score is 25):
    1. ≤ 8 for 16 or more years of education
    2. ≤ 4 for 8-15 years of education
    3. ≤ 2 for 0-7 years of education
  3. Mini-Mental State Exam score between 20 and 24 inclusive (Exceptions for scores of 24 and 25 may be made for participants with less than 8 years of education at the discretion of the Project Director)
  4. Clinical Dementia Rating = 0.5 or 1.0
  5. NINCDS (National Institute of Neurological and Communicative Disorders and Stroke) -ADRDA (Alzheimer's Disease and Related Disorders Association) criteria for probable AD
  6. Stability of Permitted Medications for at least 4 weeks:
    1. Stable doses of antidepressants lacking significant anticholinergic side effects (if they are currently adequately treated for depressive symptoms and do not have a history of major depression within the past 1 years)
    2. Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks prior to Screening Visit
    3. Estrogen replacement therapy is permissible
    4. Gingko biloba is permissible, but discouraged
    5. Washout from psychoactive medication (e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening.

Inclusion Criteria Specific to Newly Enrolled Participants

  1. Geriatric Depression Scale score less than 6.
  2. Age between 55-90 years (inclusive).
  3. Study partner who has frequent contact with the participant (i.e., minimum average of 10 hours per week) and is available to accompany the participant to all clinic visits for the duration of the protocol.
  4. Visual and auditory acuity adequate for neuropsychological testing.
  5. Good general health with no diseases expected to interfere with the study.
  6. Participant is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal or surgically sterile).
  7. Willing and able to participate in a longitudinal imaging study.
  8. Modified Hachinski Ischemic Score less than or equal to 4.
  9. Completed six grades of education or has a good work history (sufficient to exclude mental retardation).
  10. Must speak English or Spanish fluently.
  11. Willing to undergo repeated MRIs (3Tesla) and at least two PET scans
  12. Agrees to collection of blood for genomic analysis (including GWAS (genome-wide association study) sequencing and other analysis), APOE (Apolipoprotein E) testing and biospecimen banking.
  13. Agrees to collection of blood for biomarker testing.
  14. Agrees to at least one lumbar puncture for the collection of CSF.
  15. Agrees to share genomic data and biomarker samples. Inclusion Criteria Specific to Rollover Participants"

The following additional inclusion criteria apply to all diagnostic categories for rollover participants only:

  1. Must have been enrolled and followed in ADNI-1, ADNI-GO, or ADNI-2 for at least one year.
  2. Willing and able to continue to participate in an ongoing longitudinal study. A reduced battery of tests is allowable if the participant is not able/willing to complete the full battery.

Exclusion Criteria (all CN participants):

  1. Any significant neurologic disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities

Exclusion Criteria (all MCI participants):

1. Any significant neurologic disease other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.

Exclusion Criteria (all AD participants):

1. Any significant neurologic disease other than Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.

Exclusion Criteria (all participants):

The following additional exclusion criteria apply to all diagnostic categories:

  1. Screening/Baseline MRI brain scan with evidence of infection, infarction, or other focal lesions or multiple lacunes or lacunes in a critical memory structure
  2. Subjects that have any contraindications for MRI studies, including the presence of cardiac pacemakers, or metal fragments or foreign objects in the eyes, skin or body.
  3. Major depression, bipolar disorder as described in DSM-IV within the past 1 year. Psychotic features, agitation or behavioral problems within the last 3 months that could lead to difficulty complying with the protocol.
  4. Currently treated with medication for obsessive-compulsive disorder or attention deficit disorder.
  5. History of schizophrenia (DSM IV criteria).
  6. History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria).
  7. Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol.
  8. Clinically significant abnormalities in B12 or thyroid function tests (TFTs) that might interfere with the study. A low B12 is exclusionary, unless follow-up labs (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not physiologically significant.
  9. Residence in a skilled nursing facility.
  10. Current use of specific psychoactive medications (e.g., certain antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics). Current use of warfarin or other anticoagulants such as dabigatran, rivaroxaban and apixaban (exclusionary for lumbar puncture).
  11. Current use of any other exclusionary medications
  12. Investigational agents are prohibited one month prior to entry and for the duration of the trial.
  13. Participation in clinical studies involving neuropsychological measures being collected more than one time per year.

Exclusion Criteria Specific to AV-1451 PET:

The following criteria are exclusionary only for the AV-1451 scanning portion of the study:

  1. History of risk factors for torsades de pointes (a cardiac dysrhythmia associated with sudden death) or taking medications known to prolong the QT interval. A list of restricted medications will be provided.
  2. Have an ECG obtained prior to the AV-1451 PET scan that in the opinion of the investigator is clinically significant with regard to the subject's participation in the study. Bazett's corrected QT (QTcB) interval must be evaluated and must not exceed 458 msec in males, or 474 msec in females.
Open or close this module Contacts/Locations
Central Contact Person: ATRI Recruitment Team
Email: atri-recruit@usc.edu
Study Officials: Michael W. Weiner, MD
Study Director
University of California, San Francisco
Paul Aisen, MD
Principal Investigator
USC Alzheimer's Therapeutic Research Institute (ATRI)
Ronald Peterson, MD, PHD
Principal Investigator
Mayo Clinic
Locations:
Open or close this module IPDSharing
Plan to Share IPD: Yes
Supporting Information:
Time Frame:
Access Criteria:
URL:
Open or close this module References
Links: Description: Alzheimer's Disease Neuroimaging Initiative
Description: Laboratory of Neuro Imaging (LONI)
Description: Alzheimer's Therapeutic Research Institute
Description: Alzheimer's Disease Education and Referral Center
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services